Results

1–4 of 4 results for Michael S. Ip

Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy
Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS
Annual Meeting Talks
2024
Treatment of CRVO: SCORE2 Sub-analysis
Michael S. Ip, MD
Updates from the Field
2019
Suprachoroidal CLS-TA Plus Aflibercept Compared With Aflibercept Monotherapy for DME: Results of a Phase 2 Trial
Michael S. Ip, MD
Annual Meeting Talks
2019
SCORE2 Month 6 to Month 12 Results: 12 Month Outcomes of Treatment Change among Poor Responders at Month 6
Michael S. Ip, MD
Annual Meeting Talks
2018